|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||147.68 - 150.39|
|52-week range||142.81 - 197.00|
|Beta (3Y monthly)||1.34|
|PE ratio (TTM)||22.58|
|Earnings date||4 Feb 2019 - 8 Feb 2019|
|Forward dividend & yield||2.88 (1.85%)|
|1y target est||212.17|
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.
One Spa World to Go Public through Merger with Haymaker Acquisition Corp By John Jannarone The cruise industry is sometimes fraught with dangerous waters. But now, investors have a better way to navigate them. Meet One Spa World (OSW), the dominant health and wellness company that operates spas aboard major cruise lines such as Carnival […]
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On December 22, 2015, Celgene (CELG) issued a press release announcing the settlement of patent litigation for Revlimid with Natco Pharma, Arrow International, and parent company Watson Laboratories, which was then a wholly owned subsidiary of Allegan (AGN). Currently, Watson Laboratories is a part of Teva Pharmaceuticals (TEVA).
Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life. Taft's stimulator failed soon after it was surgically implanted. For years, medical device companies and doctors have touted spinal-cord stimulators as a panacea for millions of patients suffering from a wide range of pain disorders, making them one of the fastest-growing products in the $400 billion medical device industry.
WASHINGTON (AP) — To all the world, it looked like breast implants were safe. From 2008 to 2015, the U.S. Food and Drug Administration publicly reported 200 or so complaints annually — a tiny fraction of the hundreds of thousands of implant surgeries performed each year.
If you got trampled during a Black Friday sale and had to return home without wares, these three bargain stocks will make you feel better. Waiting in line not required.
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.
On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.
Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.
Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.
From filing its IND filing for EDIT-101 to new data on new engineered cell treatments, the genome editing company delivered just as promised in Q3.
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.
In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy
Attention dividend hunters! Allergan plc (NYSE:AGN) will be distributing its dividend of US$0.72 per share on the 14 December 2018, and will start trading ex-dividend in 4 days time on Read More...
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Brent Saunders has been the CEO of Allergan plc (NYSE:AGN) since 2014. This analysis aims first to contrast CEO compensation with other large companies. After that, we will consider the Read More...